Pharming Group to participate in March investor conference
37th Annual Roth Conference, Dana Point, CA, USA, March 16-18, 2025Anurag Relan, Chief Medical Officer, and Michael Levitan, VP Investor Relations and Corporate Communications, will participate in a fireside chat question and answer session on Monday, March 17 at 01:30pm PT/21:30 CET.
For more information about this conference, or to schedule a one-to-one meeting with Pharming's management team, please contact Pharming's Investor Relations team at investor@pharming.com or your Roth representative.
About Pharming Group N.V.Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:Pharming Group, Leiden, the NetherlandsMichael Levitan, VP Investor Relations & Corporate CommunicationsT: +1 (908) 705 1696E: investor@pharming.com
FTI Consulting, London, United KingdomSimon Conway/Alex Shaw/Amy ByrneT: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, the NetherlandsLeon MelensT: +31 6 53 81 64 27E: pharming@lifespring.nl
Attachment
Pharming attending Investor Conferences March 2025_EN_28FEB25
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
With 65% institutional ownership, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a favorite amongst the big guns
Key Insights Given the large stake in the stock by institutions, Rigel Pharmaceuticals' stock price might be vulnerable to their trading decisions 51% of the business is held by the top 9 shareholders Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. To get a sense of who is truly in control of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), it is important to understand the ownership structure of the business. With 65% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. Let's take a closer look to see what the different types of shareholders can tell us about Rigel Pharmaceuticals. Check out our latest analysis for Rigel Pharmaceuticals What Does The Institutional Ownership Tell Us About Rigel Pharmaceuticals? Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. We can see that Rigel Pharmaceuticals does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Rigel Pharmaceuticals' earnings history below. Of course, the future is what really matters. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It would appear that 15% of Rigel Pharmaceuticals shares are controlled by hedge funds. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Our data shows that BlackRock, Inc. is the largest shareholder with 9.7% of shares outstanding. Armistice Capital LLC is the second largest shareholder owning 8.5% of common stock, and Morgan Stanley, Investment Banking and Brokerage Investments holds about 8.3% of the company stock. Furthermore, CEO Raul Rodriguez is the owner of 0.8% of the company's shares. We did some more digging and found that 9 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. Insider Ownership Of Rigel Pharmaceuticals While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Shareholders would probably be interested to learn that insiders own shares in Rigel Pharmaceuticals, Inc.. As individuals, the insiders collectively own US$5.5m worth of the US$392m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling. General Public Ownership With a 19% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Rigel Pharmaceuticals. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. Next Steps: It's always worth thinking about the different groups who own shares in a company. But to understand Rigel Pharmaceuticals better, we need to consider many other factors. For example, we've discovered 1 warning sign for Rigel Pharmaceuticals that you should be aware of before investing here. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 minutes ago
- Yahoo
Earnings Release: Here's Why Analysts Cut Their Columbia Sportswear Company (NASDAQ:COLM) Price Target To US$57.50
Columbia Sportswear Company (NASDAQ:COLM) just released its latest second-quarter results and things are looking bullish. Revenues beat expectations coming in atUS$605m, ahead of estimates by 2.9%. Statutory losses were somewhat smaller thanthe analysts expected, coming in at US$0.19 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Following last week's earnings report, Columbia Sportswear's nine analysts are forecasting 2025 revenues to be US$3.39b, approximately in line with the last 12 months. Statutory earnings per share are expected to decline 17% to US$3.40 in the same period. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$3.40b and earnings per share (EPS) of US$3.48 in 2025. The analysts seem to have become a little more negative on the business after the latest results, given the minor downgrade to their earnings per share numbers for next year. See our latest analysis for Columbia Sportswear It might be a surprise to learn that the consensus price target fell 12% to US$57.50, with the analysts clearly linking lower forecast earnings to the performance of the stock price. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Columbia Sportswear, with the most bullish analyst valuing it at US$79.00 and the most bearish at US$40.00 per share. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business. Of course, another way to look at these forecasts is to place them into context against the industry itself. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 1.6% by the end of 2025. This indicates a significant reduction from annual growth of 5.8% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 5.6% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Columbia Sportswear is expected to lag the wider industry. The Bottom Line The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Columbia Sportswear's revenue is expected to perform worse than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Columbia Sportswear's future valuation. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Columbia Sportswear analysts - going out to 2027, and you can see them free on our platform here. You should always think about risks though. Case in point, we've spotted 2 warning signs for Columbia Sportswear you should be aware of, and 1 of them shouldn't be ignored. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
One Reading International Insider Raised Stake By 44% In Previous Year
From what we can see, insiders were net buyers in Reading International, Inc.'s (NASDAQ:RDI ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it. Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. The Last 12 Months Of Insider Transactions At Reading International The insider, Steven Lucas, made the biggest insider sale in the last 12 months. That single transaction was for US$54k worth of shares at a price of US$1.36 each. That means that an insider was selling shares at around the current price of US$1.33. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern. Steven Lucas was the only individual insider to sell over the last year. Douglas McEachern bought a total of 41.50k shares over the year at an average price of US$1.75. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below! Check out our latest analysis for Reading International Reading International is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying. Reading International Insiders Are Selling The Stock The last quarter saw substantial insider selling of Reading International shares. In total, insider Steven Lucas dumped US$54k worth of shares in that time, and we didn't record any purchases whatsoever. This may suggest that some insiders think that the shares are not cheap. Does Reading International Boast High Insider Ownership? I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data indicates that Reading International insiders own about US$6.3m worth of shares (which is 14% of the company). We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. We do generally prefer see higher levels of insider ownership. So What Does This Data Suggest About Reading International Insiders? An insider hasn't bought Reading International stock in the last three months, but there was some selling. In contrast, they appear keener if you look at the last twelve months. But insiders own relatively little of the company, from what we can see. So we can't be sure that insiders are optimistic. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Be aware that Reading International is showing 5 warning signs in our investment analysis, and 1 of those can't be ignored... Of course Reading International may not be the best stock to buy. So you may wish to see this free collection of high quality companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
